SOURCE: Avita Medical

Avita Medical

June 17, 2015 06:00 ET

Avita Medical Announces Notice of Allowance of 2nd U.S. Patent Application

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Jun 17, 2015) - Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/223,577. The allowed application is directed to the novel composition of matter in the form of an epithelial cell suspension, in connection with the Company's proprietary platform of regenerative products (ReCell®, ReNovaCell™ and ReGenerCell™).

"This newly allowed application further establishes our US patent coverage," commented Adam Kelliher, CEO of Avita. "Having a strong IP platform in place is a crucial part of our strategy as we work towards US regulatory approval, and entry into the market."

The allowed application provides broad protection for the autologous, non-cultured cell suspension prepared peri-operatively and directly applied to the patient. Avita has a robust intellectual property portfolio for its regenerative technology platform. ReCell®, ReGenerCell™ and ReNovaCell™ are protected by a family of patents and patent applications covering the unique composition of an epithelial suspension, method of production, device and automation for generating the epithelial suspension. Currently, pending worldwide patents and applications will expire in 2022-2034. Additional filings having a later expiration date will be made as Avita continues to invent in the regenerative medicine field.

ABOUT AVITA MEDICAL LIMITED

Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Contact Information

  • FOR FURTHER INFORMATION:

    Avita Medical Ltd
    Adam Kelliher
    Chief Executive Officer
    Phone: +44 (0) 1763 269 772
    Email: akelliher@avitamedical.com

    Avita Medical Ltd
    Tim Rooney
    Chief Financial Officer
    Phone: + 1 (818) 356-9400
    Email: trooney@avitamedical.com

    Avita Medical Ltd
    Gabriel Chiappini
    Company Secretary
    Phone:+61(0) 8 9474 7738
    Email: gabriel@laurus.net.au